2314-PUB: No Clinical Factors, Except Baseline HbA1c, Can Predict Glycemic Response to Dulaglutide: Real-World Data in Korean Patients

Abstract

Background: Dulaglutide, a once weekly glucagon-like peptide-1 receptor agonist, demonstrated efficacy and safety through several randomized controlled trials. The aim of our study was to evaluate glycemic response and to find the clinical factors useful in predicting glycemic response to dulaglutide in Korean patients with type 2 diabetes mellitus (T2DM). Materials and Methods: We retrospectively reviewed medical records of T2DM patients treated with dulaglutide over 6 months in Chonnam National University Hwasun Hospital. Only patients who had baseline and serial HbA1c results (3 months and 6 months) after starting dulaglutide were included. We defined the good response as achieving HbA1c reduction ≥1.0% after 6-months’ treatment with dulaglutide. Clinical factors analyzed for prediction of glycemic response included age, sex, duration of T2DM, HbA1c, BMI, HOMA-β, and HOMA-IR. Results: Among 77 patients, 38 patients (49.4%) achieved HbA1c reduction ≥1.0% after 6 months. Mean HbA1c level decreased from 8.78% at baseline to 8.03% at 6 months after treatment. Mean HbA1c reduction was -1.06% (95% confidence interval (CI); -1.45 and -0.67) at 3 months and -0.75% (95% CI; -1.27and -0.24) at 6 months after treatment. Mean weight reduction was 3.2 kg at 6 months. In subgroup analysis for predicting glycemic response to dulaglutide, only baseline HbA1c was associated with good response to dulaglutide in multivariate logistic regression analysis. Conclusion: Dulaglutide is effective for glycemic control and higher baseline HbA1c is associated with good glycemic response to dulaglutide in Korean type 2 DM patients. Disclosure J. Yoon: None. A. Hong: None. H. Kim: None. H. Kang: None.